Transthyretin-Associated Amyloidosis Outcome Survey (THAOS) (THAOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00628745|
Recruitment Status : Recruiting
First Posted : March 5, 2008
Last Update Posted : January 2, 2020
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin-associated amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate.
The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.
|Condition or disease||Intervention/treatment|
|Transthyretin Mutations Transthyretin Amyloidosis||Other: None. Observational Study.|
|Study Type :||Observational|
|Estimated Enrollment :||1 participants|
|Official Title:||TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS OUTCOMES SURVEY (THAOS): A GLOBAL, MULTI-CENTER, LONGITUDINAL, OBSERVATIONAL SURVEY OF PATIENTS WITH DOCUMENTED TRANSTHYRETIN (TTR) MUTATIONS OR WILD-TYPE TTR AMYLOIDOSIS|
|Actual Study Start Date :||July 27, 2007|
|Estimated Primary Completion Date :||June 16, 2021|
|Estimated Study Completion Date :||June 16, 2021|
Other: None. Observational Study.
- The objectives of THAOS are to describe the population of patients affected with TTR amyloidosis and to enhance the understanding of the disease natural history, including the variability and progression of the hereditary and acquired forms of disease. [ Time Frame: Dec 2007 to June 2021 ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00628745
|Contact: Pfizer CT.gov Call Center||1-800-718-1021||ClinicalTrials.gov_Inquiries@pfizer.com|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|